Bookbuilding IPO | ₹[.] Cr | Listing at BSE, NSE |
SEBI has approved the Initial Public Offer (IPO) of Sahajanand Medical Technologies Ltd. on November 17, 2025. The company will proceed with next steps to launch the Initial Public Offer (IPO) subject to market conditions and other approvals. The SEBI approval is valid for 12 months.
Sahajanand Medical Technologies Ltd. IPO is a Book Build Issue consisting entirely of an offer for sale of upto 2.76 crore shares.
The equity shares are proposed to be listed on NSE and BSE. Motilal Oswal Investment Advisors Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue. Key details like IPO dates, IPO price bands and lot size are yet to be announced.
Refer to Sahajanand Medical Technologies IPO DRHP for more details.
| IPO Date | [.] |
| Listing Date | [.] |
| Face Value | ₹1 per share |
| Price Band | |
| Lot Size | |
| Sale Type | OFS only |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 2,76,44,231 shares (agg. up to ₹[.] Cr) |
| Offer for Sale | 2,76,44,231 shares of ₹1 (agg. up to ₹[.] Cr) |
| Share Holding Pre Issue | 10,14,03,232 shares |
| Share Holding Post Issue | 10,14,03,232 shares |
| Description | Date |
|---|---|
| Filed with SEBI/Exchange | Fri, Jul 25, 2025 |
| SEBI/Exchange approval received | Mon, Nov 17, 2025 |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Offer |
| Retail Shares Offered | Not less than 35% of the Net Offer |
| NII Shares Offered | Not less than 15% of the Net Offer or the Net Offer |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Up to Rs 2 Lakhs | Yes |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Founded in 2001 by Mr. Dhirajlal Kotadia, Sahajanand Medical Technologies Ltd. is a medical device company focused on Class III and Class C/D devices, primarily in the fields of vascular and structural heart intervention. The company was the first globally to receive CE certification for a drug-eluting stent (DES) with a biodegradable polymer—Infinnium.
The product portfolio spans three key categories:
Sahajanand operates two R&D centers—one in India and one in Thailand—supported by a team of 102 professionals, including biomedical engineers and clinical research specialists. The company has built a robust intellectual property base, with 102 patents granted globally and 71 pending patent applications, along with five design registrations in India.
Key products such as Supraflex Cruz (DES), Hydra (TAVI), and Cocoon (Occluders) are backed by 72 clinical studies, and are widely accepted in over 76 countries across Europe, Asia, and other regions. The global distribution strategy includes direct operations in key European markets (Germany, Spain, France, UK), hybrid models in India (serving hospitals like Narayana Hrudayalaya Limited), and distributor-led entry in markets such as Italy.
International market adoption is reinforced by endorsements from key opinion leaders (KOLs), successful government tenders, and partnerships with major Group Purchasing Organizations (GPOs) in Europe.
The company follows a “House of Brand” strategy, developing and commercializing clinically differentiated products under recognized brand names like Supraflex Cruz, Hydra, and Cocoon.
As of March 31, 2025, Sahajanand Medical Technologies employed 1,458 full-time staff, 24 consultants, and 818 contract-based personnel across its operations.
Sahajanand Medical Technologies Ltd.'s revenue increased by 14% and profit after tax (PAT) rose by 442% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 1,094.90 | 970.58 | 911.63 |
| Total Income | 1,035.96 | 908.59 | 803.28 |
| Profit After Tax | 25.15 | -7.35 | 11.93 |
| EBITDA | 110.77 | 110.05 | 110.77 |
| NET Worth | 545.23 | 526.30 | 539.21 |
| Reserves and Surplus | 580.71 | 556.57 | 563.35 |
| Total Borrowing | 224.96 | 175.27 | 132.18 |
| Amount in ₹ Crore | |||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | The company will not receive any proceeds from the Offer. |
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 3.68% |
| ROCE | 10.37% |
| RoNW | 3.73% |
| PAT Margin | 2.45% |
| EBITDA Margin | 12.49% |
| Pre IPO | Post IPO | |
|---|---|---|
| Promoter Holding | 40.92% |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | BRLMs' fees and commissions (including underwriting commission) | |
| 2 | Brokerage, selling commission, bidding charges, processing fees and bidding charges for the Members of the Syndicate, Registered Brokers, SCSBs, RTAs and CDPs (1)(2)(3)(4) | |
| 3 | Fees payable to the Registrar to the Offer | |
| 4 | Other expenses: | |
| 5 | Listing fees, SEBI filing fees, BSE & NSE processing fees, book building software fees and other regulatory expenses | |
| 6 | Printing and stationery expenses | |
| 7 | Fees payable to the legal counsel | |
| 8 | Advertising and marketing expenses for the Offer | |
| 9 | Fees payable to other parties to the Offer including but not limited to the Statutory Auditors, independent chartered accountants and industry report provider |
Sahajanand Medical Technologies IPO is a main-board IPO of 2,76,44,231 equity shares of the face value of ₹1 aggregating up to ₹[.] Crores. The issue is priced at To be declared. The minimum order quantity is .
The Sahajanand Medical Technologies IPO open and close dates are not available as of now.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Sahajanand Medical Technologies IPO using UPI as a payment gateway. Zerodha customers can apply in Sahajanand Medical Technologies IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Sahajanand Medical Technologies IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Sahajanand Medical Technologies IPO dates are not announced. Please check back again after some time.
Sahajanand Medical Technologies IPO lot size and the minimum order quantity is not available at this time. Please check again later.
You can apply in Sahajanand Medical Technologies IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Sahajanand Medical Technologies IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Sahajanand Medical Technologies IPO allotment status.
The Sahajanand Medical Technologies IPO listing date is not yet announced. The tentative date of listing is .
